AQP One Brings JBA AICare™ and BioBaseline™ GLP-1 Modeling to Metabolic Health

Garden Grove, Calif. — AQP One, Inc., a U.S.-based health technology manufacturer, today announced the continued expansion of its FDA-listed JBA AICare™ Physiological Intelligence Platform with BioBaseline™ Metabolic Modeling and GLP-1-related trend intelligence capabilities.

The initiative aligns the company with the rapidly growing $600+ billion global metabolic health market, encompassing obesity management, diabetes care, cardiometabolic monitoring, and preventive wellness technologies.

Metabolic dysfunction is widely recognized as a contributing factor to cardiovascular disease, insulin resistance, obesity, and systemic inflammation – conditions affecting more than one billion individuals worldwide. Researchers increasingly emphasize the importance of longitudinal metabolic awareness, as cardiometabolic risk often develops gradually rather than abruptly.

Traditional metabolic assessment methods, including fasting glucose and HbA1c testing, provide important clinical information but are typically episodic in nature. Emerging research suggests that metabolic variability and directional physiological changes over time may offer additional context for understanding cardiometabolic balance.

The BioBaseline™ Metabolic framework is designed to apply adaptive AI-based modeling to interpret:

• Blood glucose directional trends

• Cardiovascular response dynamics

• Metabolic variability patterns over time

• GLP-1-related regulatory pathway indicators

Rather than relying on isolated readings, the evolving BioBaseline™ architecture is intended to establish individualized reference ranges and interpret directional shifts relative to each user’s ongoing physiological patterns. The framework is being progressively expanded as part of the company’s multi-phase platform development strategy.

“Metabolic health is dynamic,” said Tracy (Trang) Nguyen, Founder of AQP One. “Our goal is to translate complex physiological signals into understandable trend intelligence that supports long-term awareness.”

The JBA AICare™ Ring and Band are FDA-listed wearable devices developed in alignment with the U.S. Food and Drug Administration’s general wellness framework. Both devices are eligible for purchase using Flexible Spending Accounts (FSA) and Health Savings Accounts (HSA).

All metabolic, glucose, and GLP-1-related outputs are estimated, non-invasive, trend-based wellness indicators intended for general wellness purposes only. The system is not intended to measure circulating GLP-1 levels directly and is not designed to diagnose, treat, cure, or prevent disease.

Founded within the AQ Pharmaceuticals organization established in 2000, AQP One integrates healthcare experience with AI-driven wearable innovation as it advances its long-term vision of physiological intelligence infrastructure.

As artificial intelligence continues reshaping preventive health technologies, AQP One believes individualized baseline modeling may play an increasing role in next-generation metabolic awareness tools.

Tracy (Trang) Nguyen

AQ Pharmaceuticals, Inc.
+1 714-903-1009